COMMON STOCK AND STOCK-BASED COMPENSATION	9 Months Ended
COMMON STOCK AND STOCK-BASED COMPENSATION	Jan. 27, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
COMMON STOCK AND STOCK-BASED COMPENSATION	6. COMMON STOCK AND STOCK-BASED COMPENSATION Restricted Stock Awards ("RSAs") In fiscal 2016, the Compensation Committee of the Board of Directors authorized a new long-term incentive program (the “LTIP”) for key employees consisting of performance-based restricted stock awards (“RSAs”) and time-based restricted stock units (“RSUs”). Additionally, in the first quarter of fiscal 2018, the Compensation Committee awarded a maximum of 117,113 RSAs to additional key members of management under the LTIP. In the aggregate, the number of RSAs earned will vary based on performance relative to established goals for fiscal 2020 EBITDA, with 50% of the target shares earned for threshold performance (representing 410,538 shares), 100% of the target shares earned for target performance (representing 821,075 shares) and 150% of the target shares earned for maximum performance (representing 1,231,613 shares). In prior periods, the Company has been recording the RSA compensation expense based on target performance. Per ASC 718 accounting guidance, management is required in each reporting period to determine the fiscal 2020 EBITDA level that is "probable" (70% confidence) for which a performance condition will be achieved. During the third quarter of fiscal 2018, management determined that, mainly due to lower projections for our Dabir business, it is currently not probable that the Company will meet the fiscal 2020 target consolidated EBITDA performance level of $221.0 million. The adverse timing of revenue is a result of hospital adoption patterns (initial care setting penetration and expansion) being slower and more gradual than originally planned for our Dabir Surfaces business. On January 27, 2018, the Company recorded RSA compensation expense based on the threshold EBITDA performance level of $198.9 million. As a result, the Company recorded a $6.0 million compensation expense reversal in the third quarter of fiscal 2018 related to prior periods for these performance-based RSAs. At the threshold level of performance, the expected expense for the RSAs is $12.9 million through fiscal 2020. In the three and nine months ended January 27, 2018, the Company recorded a net reversal of expense of $5.4 million and $2.2 million, respectively, in compensation expense related to the RSAs based on threshold levels. These amounts are inclusive of the $6.0 million compensation expense reversal discussed above. During the three and nine months ended January 28, 2017, the Company recorded $1.4 million and $4.4 million, respectively, in compensation expense related to the RSAs, based on target levels. In future reporting periods, if management makes a determination that exceeding the threshold level is probable for fiscal 2020, an appropriate adjustment to compensation expense will be recorded in that period. In addition, if management makes a determination that it is not probable the Company will meet the threshold level for fiscal 2020, a reversal of compensation expense will be recorded in that period. The adjustments could be material to the financial statements. Restricted Stock Units ("RSUs") In the first quarter of fiscal 2018, the Compensation Committee awarded 23,175 RSUs to Methode management. In the aggregate, the Company has granted 631,175 RSUs to key employees, of which 567,175 are still outstanding. The RSUs are subject to a vesting period, with 30% vesting on April 28, 2018, 30% vesting on April 27, 2019 and 40% vesting on May 2, 2020. The total expense for the RSUs is expected to be $19.5 million through fiscal 2020. During the three and nine months ended January 27, 2018, the Company recorded $1.5 million and $4.5 million, respectively, of compensation expense related to the RSUs. During the three and nine months ended January 28, 2017, the Company recorded $1.4 million and $4.2 million, respectively, in compensation expense related to the RSUs. Director Awards During the first quarter of fiscal 2018, the Company issued 24,000 shares of common stock to our independent directors, all of which vested immediately upon grant. We recorded $1.0 million of compensation expense related to these shares during the nine months ended January 27, 2018.

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.